Follow The Filings

EW Edwards Lifesciences

Health Care, filed as EDWARDS LIFESCIENCES CORP (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 1 Owner
  • Max 0.0%
  • $258K

Who owns this now

Largest portfolio weights among holders, up to 0.0% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners 0.03%

Who owns EW

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 0.03% Hold 2,994 $258K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by EW's executives, directors and 10% owners in the last 12 months, from their Form 4s

All EW insider trades
  • None no insider bought on the open market
  • $13.2M sold by 7 insiders outside a trading plan
  • $14.5M sold by 4 insiders under 10b5-1 plans
  1. Daniel J. Lippis Cvp, Tavr
    Planned sale
    $53K 619 shares at $85.65 1.5% of stake
    Traded Oct 8 Filed Oct 8
    ↗
  2. Daniel J. Lippis Cvp, Tavr
    Planned sale
    $54K 619 shares at $87.51 1.5% of stake
    Traded Sep 11 Filed Sep 11
    ↗
  3. Andrew M. Dahl SVP, Corporate Controller
    Sale
    $50K 544 shares at $91.06 3.5% of stake
    Traded Aug 31 Filed Aug 31
    ↗
  4. Annette Bruls Cvp, Emeacla
    Sale
    $238K 2,644 shares at $89.98 13% of stake
    Traded Aug 28 Filed Aug 28
    ↗
  5. Daveen Chopra CVP, TMTT, Surgical & IHFM
    Sale
    $2.9M 31,800 shares at $91.02 42% of stake
    Traded Aug 26 Filed Aug 26
    ↗
  6. Wayne Markowitz Cvp, Japac
    Sale
    $113K 1,240 shares at $91.47 5.8% of stake
    Traded Aug 26 Filed Aug 26
    ↗
  7. Daniel J. Lippis Cvp, Tavr
    Planned sale
    $57K 619 shares at $92.03 1.5% of stake
    Traded Aug 11 Filed Aug 11
    ↗
  8. Wayne Markowitz Cvp, Japac
    Sale
    $13K 146 shares at $86.03 0.7% of stake
    Traded Jul 30 Filed Jul 30
    ↗
  9. Wayne Markowitz Cvp, Japac
    Sale
    $819K 9,628 shares at $85.06 31% of stake
    Traded Jul 28 Filed Jul 28
    ↗
  10. Bernard J Zovighian CEO
    Sale
    $245K 2,921 shares at $83.93 25% of stake
    Traded Jul 27 Filed Jul 27
    ↗
  11. Daniel J. Lippis Cvp, Tavr
    Planned sale
    $57K 619 shares at $91.70 1.5% of stake
    Traded Jul 10 Filed Jul 10
    ↗
  12. Daniel J. Lippis Cvp, Tavr
    Planned sale
    $57K 619 shares at $91.40 1.5% of stake
    Traded Jun 30 Filed Jun 30
    ↗
  13. Bernard J Zovighian CEO
    Planned sale
    $46K 523 shares at $87.92 4.3% of stake
    Traded Jun 17 Filed Jun 17
    ↗
  14. Andrew M. Dahl SVP, Corporate Controller
    Sale
    $49K 568 shares at $86.08 3.6% of stake
    Traded May 29 Filed May 29
    ↗
  15. Donald E Bobo Jr. CVP,Strategy/Corp Development
    Sale
    $2M 23,145 shares at $86.42 19% of stake
    Traded May 27 Filed May 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 36 share withholdings for taxes, 30 option exercises, 22 stock grants, and 15 gifts.

Congress

8 members of Congress traded EW in the last three years: 5 buys and 6 sales. 5 members listed it in 2025 annual reports.

All Congress trades
  1. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  2. Josh Gottheimer D-NJ-5Joint Sell $1K–$15K Nov 19, 2025 filed Dec 29, 2025
  3. Jefferson Shreve R-IN-6 Sell $50K–$100K May 12, 2025 filed Jun 22, 2025
  4. Bruce Westerman R-AR-4 Sell $1K–$15K Apr 21, 2025 filed May 12, 2025
  5. Robert P. Bresnahan, Jr. R-PA-8 Buy $1K–$15K Apr 8, 2025 filed May 8, 2025
  6. Jefferson Shreve R-IN-6 Buy $15K–$50K Apr 7, 2025 filed May 8, 2025

SEC filings

Recent issuer filings from EDGAR, 3 shown.

Filed Form Detail Links
8-K 5.02 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 22 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $6B $5.44B $6.07B
Gross profit $4.62B $4.32B $4.73B
Gross margin * 77.0% 79.5% 78.0%
Net income $1.4B $4.17B $1.07B
Net margin * 23.4% 76.7% 17.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $4.04B $6.29B $6.74B
Total non-current assets * $5.33B $6.77B $6.96B
Total assets $9.36B $13.06B $13.7B
Total current liabilities $1.2B $1.51B $1.81B
Total non-current liabilities * $1.45B $1.49B $1.55B
Total equity $6.65B $10B $10.34B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $0.896B $0.542B $1.6B
Cash from investing $0.174B $2.31B -$0.713B
Cash from financing -$711M -$983M -$956.8M
Net change in cash $0.375B $1.91B -$0.119B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.